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Abstract
Background—Proteinuria in HIV-infected individuals has been associated with poorer 
outcomes. We examined risk factors associated with the development of proteinuria in a national 
registry of HIV-infected veterans.
Methods—21,129 HIV-infected veterans of black and white race without pre-existing kidney 
disease were receiving health care in the Veterans’ Health Administration (VHA) medical system 
between 1997 and 2011. Using the VHA electronic record system, we identified kidney-related 
risk factors (hypertension, diabetes, cardiovascular disease), and HIV-related risk factors (CD4 
lymphocyte count, HIV RNA level, hepatitis C virus, and hepatitis B virus) for developing 
proteinuria. Proteinuria was defined by 2 consecutive dipstick measures of 1+ or higher. The Fine-
Gray competing risk model was used to estimate association between clinical variables and 
incident proteinuria, while accounting for intervening mortality events.
Results—During follow-up (median=5.3 years), 7,031 patients developed proteinuria. Overall, 
black race compared with white race was associated with a higher risk of proteinuria (HR[95% 
CI]=1.51[1.43–1.59]), but the association was stronger at younger ages (p interaction<0.001). 
Age-stratified risk of proteinuria for blacks relative to whites was greatest amongst veterans<30 
years (2.19[1.66–2.89]) and the risk diminished with increasing age (1.14[0.97–1.34] for >60 
years). We found the race difference to be stronger for the outcome of 2+ or higher proteinuria 
(2.13[1.89–2.39]). Both HIV-related and traditional risk factors were also associated with incident 
proteinuria (p<0.05).
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Conclusions—Compared with whites, risk of proteinuria was higher in black veterans with 
HIV-infection, particularly at younger ages. In both races, HIV and kidney-related risk factors 




Chronic kidney disease (CKD) is defined by either reduced glomerular filtration rate (GFR) 
or by the presence of proteinuria. CKD has become an important comorbidity among human 
immunodeficiency virus (HIV)-infected persons.1 As the survival with HIV infection 
lengthens, the prevalence of CKD is projected to increase steadily.2 Proteinuria is often the 
earliest manifestation of CKD, and is far more prevalent in HIV-infected persons than in 
similarly aged HIV-negative controls.3 In addition, among HIV-infected persons, proteinuria 
is strongly associated with death, cardiovascular disease (CVD) and end-stage-renal-disease 
(ESRD).4–7 Previous cross-sectional studies have found that proteinuria is more prevalent 
among HIV-infected patients who are black8,9 and have depressed CD4 lymphocyte count.10 
However, few if any studies have evaluated the risk factors of incident proteinuria in HIV-
infected patients. To the best of our knowledge, studies have also not examined the risk 
factors for proteinuria stratified by race; nor have they compared risk factors for mild versus 
severe proteinuria among HIV-infected patients. In our prior work11 we have found that the 
exposure to tenofovir, a first-line treatment of HIV infection, was associated with increased 
risk of kidney disease events. In this paper our focus is on the associations of race and other 
risk factors for incident proteinuria in the HIV-infected patients. The purpose of our study 
was therefore to assess the clinical and demographic factors associated with the 
development of proteinuria in a prospective cohort of HIV-infected veterans. We 
hypothesized that both HIV-related and traditional CKD risk factors would contribute to 
proteinuria risk, and that the magnitude of risk factors would differ between black and white 
patients.
Methods
We conducted a retrospective cohort study of HIV-infected veterans in the Department of 
Veterans’ Affairs (VA) HIV Clinical Case Registry (CCR) between 1997 and 2011. We 
studied the association between risk factors and development of incident proteinuria in this 
national sample of HIV-infected US veterans. Geographically, the Veterans Health 
Administration (VHA) is national in scope and offers low-cost, comprehensive clinical 
services to US veterans.12 The VA HIV CCR actively monitors all HIV-infected persons 
receiving care in the VA nationally, and automatically extracts demographic, clinical, 
laboratory, pharmacy, utilization, and death information from the VA electronic medical 
record to a centralized database.13
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We identified 65,675 HIV-infected persons receiving ambulatory care in the VA since 1984. 
Among these individuals, 30,632 patients initiated ARV therapy in the modern era of 
combination ARV therapy (after 1997). Inclusion criteria for patients for this study were 
HIV-infected veterans who were treatment-naïve (i.e. no prior exposure to any ARV) at the 
time they entered clinical care in the VHA system, and who subsequently received mono or 
combined ARV after 1997 with regular care and laboratory monitoring. We included 
patients with defined race of black or white excluding those of other races or missing race. 
We excluded patients with prevalent kidney failure (receipt of chronic dialysis treatment or 
kidney transplant), and those who did not have at least one outpatient visit and at least one 
follow-up proteinuria assessment. We also excluded those with proteinuria present at 
baseline, leaving 21,129 patients in the analytic cohort. Baseline was defined as the date of 
starting antiretroviral therapy and they were followed until the first occurrence of proteinuria 
or death.
Outcomes
The primary outcome was the time from baseline to the time of the first occurrence of 
proteinuria, defined as two consecutive urinalyses demonstrating a dipstick reading of 1+ (30 
mg/dL) or higher. As a second outcome, we defined “severe proteinuria” as two consecutive 
dipstick measures of 2+ (100 mg/dL) or higher. For both outcomes, the event was deemed to 
have occurred at the time of the second of the two consecutively positive urinalyses.
Predictors and Covariates
Predictor variables were factors hypothesized to be associated with proteinuria in HIV-
infected patients. The demographic predictors included age, sex, and race; traditional risk 
factors included diabetes, hypertension, CVD, dyslipidemia, and eGFR. The HIV-related 
characteristics included illicit drug use, CD4 lymphocyte count, HIV RNA level, and 
hepatitis B and hepatitis C co-infection. Additional candidate predictors included body mass 
index (BMI), low density lipoprotein (LDL), high density lipoprotein (HDL), total 
cholesterol, and serum glucose. Age was categorized as <30, 30–40, 41–50, 51–60, and >60 
years. BMI was categorized as <20, 20–25, 26–30, and >30 kg/m2. Absolute CD4 
lymphocyte count was categorized as ≤ =200 cells/mm3 and >200 cells/mm3. Plasma HIV 
RNA level was categorized as ≤ =400 copies/mL, 401–10,000 copies/mL, 10,001–100,000 
copies/mL, and >100,000 copies/mL. Chronic hepatitis B was defined as a positive surface 
antigen test (HBsAg), and chronic hepatitis C as a positive antibody test.
Demographic characteristics were obtained from the VA or Medicare health plan 
databases.14 Diabetes, hypertension, CVD, smoking, and HIV-related characteristics were 
ascertained by validated algorithms using a combination of ambulatory diagnoses, physician 
problem lists, hospitalization discharge diagnoses, procedures, laboratory results, and 
medication prescriptions.15–19 Tobacco use was defined by inpatient or outpatient diagnostic 
codes; questions regarding tobacco use are mandatory in VA clinical care. eGFR was 
calculated using the 4-variable Modification of Diet in Renal Disease (MDRD) Study 
equation based on age, gender, race, and serum creatinine level20; the MDRD Study 
equation remains in clinical use in the VA laboratory reporting system. Baseline eGFR was 
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defined as the average of the first 2 consecutive eGFR measurements after starting ARV 
therapy separated by at least 3 months. Estimated GFR levels above 120 ml/min/1.73m2 
were capped at this level, as higher estimates are unlikely to be accurate or precise.21 At any 
given time, the most recent previous measurement was used to define time-dependent 
covariates.
Statistical Analyses
Baseline characteristics of the black and white HIV-infected veterans were compared using 
χ2 tests for categorical variables and Wilcoxon rank-sum tests for continuous variables. 
Poisson regression models were used to calculate the unadjusted rates of incident proteinuria 
(per 1000 person-years), stratified for age and race, and rates adjusted for gender, BMI, 
diabetes, hypertension, dyslipidemia, CVD, smoking, eGFR, illicit drug use, lower CD4 
lymphocyte count, higher HIV viral load, and co-infection with hepatitis B and hepatitis C. 
We investigated the combined effect of risk factors associated with the development of 
proteinuria in subjects with multiple-record data using the Fine-Gray competing risks 
analysis.22 In our cohort, failure could occur due to the onset of proteinuria (failure of 
interest), or death. To account for the potential bias due to the competing risk of death 
before onset of proteinuria, we performed the Fine-Gray competing-risks analysis, which 
extends the Cox proportional hazards model to competing-risks data by simultaneously 
evaluating hazards for the primary (proteinuria) and competing (death) events. Assumptions 
of proportional hazards were examined by computing the Schoenfeld residuals.22,23 We also 
stratified our analysis by year of diagnosis in order to determine whether the relative 
contributions of traditional CKD risk factors and HIV-related factors to proteinuria risk 
changed over time. We conducted a supplemental analysis (competing robustness of the 
primary results). Tests for interaction were performed using cross-product terms between 
race and time-dependent characteristics of interest in the model. Because of the observed 
differences in the association of age and race with proteinuria, analyses were also stratified 
by black and white race.
We also investigated whether differences in durable viral suppression between blacks and 
whites partially underlay the differences in proteinuria risk. To evaluate this, we ran our 
competing risk model initially adjusting for the demographic characteristics and then 
controlled for all the potential confounders and the viral load. The viral load was controlled 
in a time-updated fashion so this would account for changes over time in the viral 
suppression status.
Sensitivity Analysis—Since the frequency of obtaining urine dipsticks may be different 
in black and white patients, we adjusted our model for the number of times the patient was 
assessed for proteinuria.
Analyses were conducted using STATA, version 11 (StataCorp, College Station, TX) and 
SAS 9.3 (SAS Institute, Inc. Cary, NC).
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Among 21,129 included HIV-infected veterans, median age was 47 years, 97.4% were men, 
and 52.7 % were black. In general, black patients were less likely to have dyslipidemia and 
more likely to have hepatitis C virus (HCV), had lower CD4 lymphocyte count, and higher 
HIV RNA levels (Table 1).
A total of 7,031 proteinuria outcomes were observed during the study follow-up (median 
duration =5.3 years, IQR 2.3–9.2). The median time between two proteinuria measurements 
was 5 months (IQR 3–13).
As shown in Figure 1, unadjusted association of age with rate of incident proteinuria per 
1,000 patient years differed by race, with a U-shaped association of proteinuria and age in 
blacks, and a nearly monotonic association in whites. Although blacks appeared to have 
higher rates of proteinuria within each age category relative to whites, the race difference 
was greatest among younger patients below age 30 years and gradually diminished with 
increasing age. Further, the rates were not significantly different at ages > 60 years. This 
finding persisted after multivariate adjustment, the age specific rates of incident proteinuria 
per 1000 person-years for both blacks and whites are shown in Table 2. The rate ratio for 
proteinuria in the <30 year age group was 1.96 (95% CI 1.67–2.30), indicating that blacks 
were approximately 2 times more likely to have proteinuria than whites in our cohort.
After multivariable adjustment in the competing risk model, low body mass index (BMI) 
<20 kg/m2, diabetes, hypertension, dyslipidemia, cardiovascular disease (CVD), and low 
eGFR prior to the development of proteinuria were all associated with a greater risk of 
proteinuria (Table 3). HIV-related risk factors were also associated with proteinuria risk: 
plasma HIV RNA levels > 100,000 copies/mL, CD4 lymphocyte count of ≤200 cells/mm3, 
hepatitis C, and hepatitis B virus. We did not observe significant interactions between race 
and the other covariates (P interaction>0.05 in fully adjusted models) except for the 
interaction between age and race for the risk of proteinuria (p<0.001) and eGFR and race 
(p=0.0012) in our multivariable analysis. Although higher eGFR was associated with a 
lower risk of proteinuria in both blacks and whites, the association was somewhat stronger 
in whites (HR [95% CI]= 0.91 [0.89–0.94] vs. HR [95% CI]= 0.95 [0.93–0.96]).
In race-stratified analysis, the hazard ratios associated with the risk factors were similar in 
blacks and whites. Table 4 shows the further exploration of the race differences for risk of 
proteinuria using age-stratified multivariable analysis. The results showed a 2-fold for 
blacks vs. whites among participants below 30 years of age. With increasing age, the risk 
associated with race difference lost its significance. Given the non-linear association with 
age, we also ran our multivariable competing risk model for time to proteinuria with a linear 
and a quadratic term for age rather than the age categories as shown in Table 3. For 
estimating the risk of proteinuria, the adjusted HR for black vs. white was 1.38 (95% CI 
1.31–1.45).
Additional analyses stratified by the year of HIV diagnosis, showed a lower incidence 
among those diagnosed in more recent years. However, risk factor associations with 
proteinuria were generally consistent across the four time-periods (Supplemental Table 2). 
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Black race was consistently associated with an elevated risk of proteinuria across years of 
follow-up relative to whites; the hazard ratio for blacks relative to whites was 1.46 [95% CI: 
1.33–1.60] among persons diagnosed prior to 1997; 1.60 [1.45–1.75] for diagnosis between 
1997–1999; 1.55 [1.40–1.71] for diagnosis between 2000–2003; and 1.44 [1.28–1.62] for 
diagnosis after 2003.
On evaluating whether differences in durable viral suppression between blacks and whites 
partially underlay the differences in proteinuria risk, we found that the race effect was 
significant regardless of the effect of durable viral suppression both in simple demographic 
adjusted analysis (1.39 [1.33–1.46]) and in adjusted models excluding viral load (1.50 
[1.43–1.58]). Rather the race effect strengthened after adjusting the model for viral load 
(1.51 [1.43–1.59]).
Sensitivity Analysis
We were concerned that race might influence ascertainment of urine protein, so we adjusted 
for number of times the patient was assessed for proteinuria. The association of black race 
with proteinuria risk remained significantly stronger in this adjusted model (HR [95% CI]: 
1.50 [1.43–1.59]).
Severe Proteinuria—Of the 21,129 HIV-infected individuals in the cohort who had urine 
analyses documented, 1,390 developed severe proteinuria (Table 5). Severe proteinuria was 
defined as two consecutive dipstick measures of 2+ (100 mg/dL) or higher. After adjustment 
for confounders, individuals of black race had a 2-fold risk of severe proteinuria compared 
with white individuals. In this analysis, the interaction of race and age was less striking 
(p=0.002). The model indicated that as age increased by a decade, the risk of severe 
proteinuria observed for the race difference decreased by 19%. Among the traditional risk 
factors for kidney disease, hypertension, diabetes, CVD, and lower eGFR were each 
associated with higher risk of severe proteinuria. Multivariable-adjusted associations of the 
HIV disease risk factors such as low CD4 lymphocyte count, high viral load, hepatitis C and 
hepatitis B co-infections with severe proteinuria were also stronger.
In the stratified analysis, risk factors had similar associations among blacks and whites. HIV 
RNA level had a somewhat stronger association in blacks than in whites (p for 
interaction=0.08).
Discussion
Proteinuria is part of the definition of CKD, and is a risk marker for progression to ESRD.24 
Previous literature found that higher levels of proteinuria are independently associated with 
risk of ESRD at all levels of eGFR.25 Our study examined the risk factors for proteinuria 
among a large cohort of HIV-infected veterans. Black race has been found to be a strong risk 
factor for advanced HIV-associated nephropathy5,10 but little data are available on the risk 
of developing proteinuria in HIV-infected individuals. In addition, fewer studies have been 
conducted in the era of highly effective antiretroviral (ARV) therapy in large number of 
patients. One such study is our previous work on the association of tenofovir, a first-line 
treatment of HIV infection that is currently used in half of all the antiretroviral regimens, 
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with proteinuria.11 To our knowledge, our study is the largest cohort of HIV-infected 
veterans used to date to investigate the risk factors for the development of proteinuria.
Our study demonstrates a significant effect of race on the incidence of proteinuria and 
severe proteinuria. Furthermore, we found that the higher risk of incident proteinuria in 
blacks was particularly evident in younger age groups. In our cohort, the younger blacks 
compared to the younger whites were not under control for hypertension and diabetes 
(Supplemental Table 1). Another potential reason could be that risks in younger blacks are 
driven by early susceptibility due to genetic polymorphic difference (i.e. interaction of 
APOL1 genotype) that may contribute to the increasing risk of proteinuria.26,27 Several 
studies have demonstrated significant disparities in HAART utilization according to race. 
HIV-infected blacks present for care in more advanced stages of disease28 and are less likely 
to receive HAART than are HIV-infected whites, even among patients in care.29 The 
differences in proteinuria risk across races could be further attributed to the differences in 
durable viral suppression between blacks and whites as demonstrated in our study. Since 
black race is a strong risk factor for HIV associated renal disease, as has previously been 
documented,7,30 and young black men are disproportionately affected,31 the stronger 
association of black race with proteinuria in the younger groups is not surprising. 
Nevertheless, these striking racial differences with age in development of proteinuria among 
patients with HIV highlight the critical need for studies devoted to the understanding of 
underlying disease mechanisms for HIV-related kidney disease, particularly among blacks.
Previous studies investigating predictive factors of CKD have identified hypertension and 
diabetes to be independently related to CKD.32,33 It is noteworthy that in the competing risk 
framework, the key established kidney and cardiovascular risk factors of kidney dysfunction 
were associated with the risk of incident proteinuria, including dyslipidemia and CVD along 
with diabetes and hypertension. Interestingly, in our study these traditional risk factors 
exhibited a stronger association with severe proteinuria.
Our study also demonstrated that several HIV-related risk factors including elevated HIV 
RNA level, absolute CD4 lymphocyte count, hepatitis C, and hepatitis B co-infection are 
associated with proteinuria and their association is much stronger with severe proteinuria. 
Our finding of higher HIV RNA levels and lower CD4 lymphocyte counts predictive of 
proteinuria in multivariable analysis, was consistent with the findings from the Women’s 
Interagency HIV Study.10 The significance of HIV RNA level and CD4 lymphocyte count 
in this analysis supports the hypothesis that HIV-related renal diseases34,35 represent a direct 
infection of the virus within the kidney and viral suppression caused by highly active 
antiretroviral therapy ( HAART) likely results in improvement or stabilization of renal 
function.21 In this cohort, a positive test for the hepatitis C antibody was also an independent 
predictor of proteinuria.
Our study is unique as it is a large, national registry investigating incident proteinuria with 
the relatively uniform health care system available to US veterans and the reliable data 
source for both the predictor variables and the outcome of proteinuria. Due to the large size, 
we have substantial power in our cohort to compare risk factors among the black and white 
veterans. Prior studies that have identified risk factors of proteinuria in HIV infection were 
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cross-sectional and therefore causality cannot be inferred. Our database includes 21,129 
HIV-infected veterans who met the inclusion criteria and were followed for a median 
duration of 5.3 years. This represents the largest study to evaluate incident proteinuria with 
longitudinal data on urine protein excretion in black and white race.
Despite the strengths mentioned of this study, there are certain limitations. First, this study is 
predominantly in male veterans receiving care in the Department of VA Health Care 
System, so results may not be generalizable to women, non-veterans, or racial and ethnic 
groups other than blacks and whites. Second, assessment of proteinuria was at discretion of 
clinicians and not part of a protocol. Third, we did not study any specific glomerular or 
tubular markers of injury due to sustained proteinuria. Fourth, we cannot determine the role 
of apolipoprotein L1 (APOL1) genotype as a determinant of risk for proteinuria in the HIV-
infected blacks. Previous studies, however, have demonstrated an 8–13% prevalence of the 
APOL1 genotype in HIV-infected blacks.26,27 Fifth, we excluded patients with missing race 
information and those who reported being American Indians/Native Alaskan, Pacific 
Islander/Native Hawaiian or Asian (19%) from our cohort. Sixth, we did not have HCV 
RNA data to confirm chronic HCV infection, and it is likely that Hepatitis C resolved in 
some patients.
In summary, we found remarkably strong associations between black race and incident 
proteinuria that were strongest among younger HIV-infected individuals and for the 
outcome of severe proteinuria. These differences raise the need to understand the alarmingly 
high risk of proteinuria in blacks. Further, clinicians should recognize that both the 
traditional and HIV-related risk factors are important contributors to the onset of proteinuria. 
The potential impact of these results includes the possibility of improving intervention and 
prevention/control and delay the onset of proteinuria.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Unadjusted incidence rates of dipstick proteinuria, stratified by race and age (bars with 95% 
CI). Numbers on top of the columns represent unadjusted hazard ratios for the race 
difference within age categories (with 95% CI).
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